The rising interest in potent weight management has spurred considerable investigation into groundbreaking treatments. Recently , Retatrutide, a twin-action glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor stimulator, has exhibited encouraging results in patient trials, indic